U.S. Markets close in 5 hrs 1 min
  • S&P 500

    3,244.73
    -65.38 (-1.98%)
     
  • Dow 30

    26,187.41
    -471.70 (-1.77%)
     
  • Nasdaq

    10,874.74
    -310.85 (-2.78%)
     
  • Russell 2000

    1,535.91
    -25.67 (-1.64%)
     
  • Crude Oil

    35.52
    -0.65 (-1.80%)
     
  • Gold

    1,879.50
    +11.50 (+0.62%)
     
  • Silver

    23.52
    +0.16 (+0.68%)
     
  • EUR/USD

    1.1681
    +0.0003 (+0.0234%)
     
  • 10-Yr Bond

    0.8520
    +0.0170 (+2.04%)
     
  • Vix

    39.30
    +1.71 (+4.55%)
     
  • GBP/USD

    1.2936
    +0.0013 (+0.0970%)
     
  • USD/JPY

    104.6620
    +0.0520 (+0.0497%)
     
  • BTC-USD

    13,348.59
    +49.74 (+0.37%)
     
  • CMC Crypto 200

    260.77
    -2.87 (-1.09%)
     
  • FTSE 100

    5,549.00
    -32.75 (-0.59%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

ViroPharma up, FDA lifts ban

The biotech's shares rose 7.6% to 30.31 after the FDA allowed it to resume testing of a product with Halozyme Therapeutic (HALO). On Aug. 2, the FDA halted the testing of a combination of ViroPharma's (VPHM) best-selling drug Cinryze, used to treat a rare disorder called hereditary angioedema, with Halozyme's Enhanze platform for delivering the drug subcutaneously. The cited reason was safety concerns. The FDA advised ViroPharma to amend the study protocol. Halozyme shares rose 24% to 7.95.